Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease스파이크 및 뉴클레오캡시드 단백질을 발현하는 재조합 ACAM2000 백시니아 바이러스를 사용한 단일 면역은 SARS-CoV-2 유발 임상 질병으로부터 햄스터를 보호합니다Article Published on 2022-05-112022-09-11 Journal: Journal of Virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] ACAM2000 Antibody titer Antigen antigens Breakthrough infection candidate clinical Combination competent Continuous COVID-19 COVID-19 vaccine COVID-19 vaccines deleted demonstrated described develop E3L Efficacy ENhance expected expressed expressing hamster hamsters highlight host range human cells immune responses Immunity immunization immunogenic Increasing induce Infection initial innate immune responses intramuscular investigated K3L long-lasting lymphocyte N protein Neutralizing antibody titer neutrophil Neutrophil-to-lymphocyte ratio nucleocapsid nucleocapsid antigen nucleocapsid antigens nucleocapsid protein Nucleocapsid proteins ortholog platform poxvirus Protective Protein recombinant recombinant COVID-19 vaccine Recovery time reduced reduced viral loads replaced SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 variant SARS-CoV-2 variants shorter recovery time shown significantly spike spike and nucleocapsid proteins the SARS-CoV-2 the Spike the vaccine Vaccine vaccine candidate vaccinia vaccinia virus variants Viral virus virus replication weight loss were expressed [DOI] 10.1128/jvi.00389-22 PMC 바로가기 [Article Type] Article
Icon arrays reduce concern over COVID-19 vaccine side effects: a randomized control studyRandomized Controlled Trial Published on 2022-05-072022-10-04 Journal: Cognitive research: principles and implications [Category] COVID19(2023년), SARS, 임상, [키워드] Administered administration American aversion Blood CDC changes in COVID-19 vaccine COVID-19 vaccines Icon increases in MOST Prevent prevented randomized control study reduce risk Side effect significantly the vaccine Vaccine Vaccine hesitancy [DOI] 10.1186/s41235-022-00387-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Design of a Recombinant Multivalent Epitope Vaccine Based on SARS-CoV-2 and Its Variants in Immunoinformatics Approaches면역정보학 접근법에서 SARS-CoV-2 및 그 변이체에 기반한 재조합 다가 에피토프 백신의 설계Article Published on 2022-05-062022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] allergen antigen epitope antigen epitopes approach B-cell epitope caused cellular conformational Coverage COVID-19 cytotoxic T lymphocyte docking effective Epidemic epitope Epitopes global public health Humoral immunity Immune simulation immunoinformatics IMPROVE in vitro in vivo Interaction linear B-cell epitope linear B-cell epitopes linker lymphocyte multivalent multivalent vaccine mutated virus Protein recombinant SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants screened strain strong interaction T lymphocyte the vaccine tlr-3 Vaccine variant variants VoC [DOI] 10.3389/fimmu.2022.884433 PMC 바로가기 [Article Type] Article
The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants변종에 따른 COVID-19 백신의 다양한 효능 수준에 대한 유통 속도의 균형 역할Article Published on 2022-05-062022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] Accessibility adverse outcome adverse outcomes attack rate caused COVID-19 COVID-19 pandemic COVID-19 vaccine deaths distribution Effectiveness Efficacy evaluated example Hospitalization hospitalizations immunization Infection initial Interaction key factor Mutation occurred pandemic public health raised reduce reducing regions SARS-CoV-2 speed Spread the vaccine understanding vaccination Vaccine variant variants [DOI] 10.1038/s41598-022-11060-8 PMC 바로가기 [Article Type] Article
Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2레플리콘 기반 mRNA 백신 후보의 박테리아 지원 경구 전달은 조상 및 델타 변이형 SARS-CoV-2로부터 보호Article Published on 2022-05-042022-09-11 Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 alphaviruses antibody antigenic diversity B.1.617.2 Bacteria Cellular immune response cellular immune responses clade contributed contributing to Coronavirus-2 COVID-19 cross-protective domain Efficacy epitope Epitopes Evolution feasible forest gene delivery hamster hamsters heptad repeat immune responses immunization immunized immunized mice Immunoglobulin lung Lungs mass vaccination membrane protein mRNA mRNA vaccine mucosal mucosal vaccine NAbs nasal Nasal cavity Neutralizing antibodies neutralizing antibody non-structural protein nsp13 offer oral Oral Immunization oral route Pneumonia principle PROTECT provide RBD Receptor binding domain recorded replicon-based respiratory Salmonella Salmonella-mediated SARS-CoV-2 secretory IgA SIgA the vaccine vaccination Vaccine vaccine efficacy variant variants Viral viral replication virus [DOI] 10.1016/j.ymthe.2022.01.042 PMC 바로가기 [Article Type] Article
A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models자가 증폭 mRNA SARS-CoV-2 백신 후보는 전임상 모델에서 안전하고 강력한 보호 면역을 유도합니다Clinical Trial Published on 2022-05-042022-09-11 Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 임상, 진단, [키워드] (Alpha) (Beta Alpha animals Antigen B.1.1.7 B.1.351 B.1.617.2 Beta biodistribution breath CD4 CD8 T cell CD8 T cell responses characterized clinical evaluation Delta demonstrated disease dose-dependent manner Efficacy elicit elicited emergency response Evidence evidence of Frequency Germinal center hamsters humans immune responses immunization immunogenicity induce Lipid nanoparticle Lipid nanoparticles LNP lower airways Messenger RNA mice mRNA neutralized no evidence of Phase 1 Protective protective immune response protective immunity RATs reduced response RNA RNA vaccines robust Safe safety profile SAM SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variants SARS-CoV-2 Wuhan strain self-amplifying mRNA Spike antigen spike-specific antibody response T cell the SARS-CoV-2 the vaccine Tolerance Toxicity upper and lower airways Vaccine vaccine candidate variants Viral Viral load Wuhan-Hu-1 [DOI] 10.1016/j.ymthe.2022.01.001 PMC 바로가기 [Article Type] Clinical Trial
Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2SARS-CoV-2에 대한 교차 반응성 점막 및 전신 항체 반응을 위한 열안정성 소단위 백신의 비강내 전달Article Published on 2022-05-032022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 addition Against Alpha angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 anti-RBD Anti-RBD antibody antibody Antibody Response Antibody responses Antibody titer Antibody titers approved Beta binding binding domain Breakthrough infection breakthrough infections chitosan circulation COVID-19 COVID-19 vaccines CpG cross-reactive delivery Delta variants domain Efficacy effort enzyme exclusion FIVE genetic material help Hesitancy IgA antibodies IgG1 IgG2a IL-12 Immunity immunization IMPROVE induce inhibited interleukin interleukin-12 intranasal intranasal vaccination intranasally isotype Laboratory mice mucosal mucosal immunity mutant oligonucleotide polypeptide Prevent PROTECT RBD RBD-specific antibodies RBD-specific antibody receptor Receptor binding domain receptor binding domain (RBD) reduce respiratory respiratory viruses response responses room temperature SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants specific antibodies stability subcutaneous vaccination subunit Subunit vaccine systemic temperature the vaccine thermostable upper respiratory tract vaccination Vaccine Vaccine development Vaccine hesitancy vaccine platform variants virus [DOI] 10.3389/fimmu.2022.858904 PMC 바로가기 [Article Type] Article
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 VaccineBNT162b2 mRNA COVID-19 백신 2~3회 투여 후 SARS-CoV-2 변이체에 대한 중화 항체 반응 평가Article Published on 2022-05-022022-09-11 Journal: JAMA Network Open [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] 95% CI Against age all age group all age groups assessment BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine booster booster vaccination cohort study conducted COVID-19 D614G variant delta variant dose group Immunity increase in induce Japanese Kobe lowest median age men Messenger RNA mRNA much higher Neutralizing antibodies neutralizing antibody Older age omicron Omicron variant other variant other variants outcome pandemic participant Participants physician Positive test positive test result recipient recipients response SARS-CoV-2 SARS-CoV-2 pandemic test results tested the SARS-CoV-2 the vaccine titer titers university vaccination Vaccine variant variants [DOI] 10.1001/jamanetworkopen.2022.10780 PMC 바로가기 [Article Type] Article
The effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffnessRandomized Controlled Trial Published on 2022-05-012022-10-04 Journal: Hypertension research : official journal of the Ja [Category] 바이오마커, 임상, 치료기술, 치료법, [키워드] administration adopted age arterial Arterial stiffness baseline Blood BNT162b2 mRNA brachial cause confidence interval COVID-19 COVID-19 pandemic COVID-19 vaccine Deterioration dose Endothelial dysfunction endothelial function evaluated High-sensitivity C-reactive protein hsCRP increase in Inflammation inflammatory markers median men Messenger RNA mRNA mRNA vaccine outcome participant Placebo Primary outcome pulse remained returned SARS-CoV-2 secondary outcome significantly the vaccine vaccination Vaccine were assessed [DOI] 10.1038/s41440-022-00876-6 PMC 바로가기 [Article Type] Randomized Controlled Trial
The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273BNT162b2 및 mRNA-1273 백신 접종에 대한 T 세포 및 B 세포 반응의 시간적 경과Article Published on 2022-05-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration age ANAs antibody antinuclear antibodies Autoimmune response autoimmune responses B-cell response BNT162b2 coronavirus correlated Course COVID-19 detectable deviation dose doses elicit ELISA epitope Epitopes examined Factor Factors first dose first vaccination form healthcare professionals IFN-γ IgA IgG immune response immune responses immune system Immunity Immunosuppressed Immunosuppression individual Infection infection with SARS-CoV-2 influence interferon interferon-γ marker median median absolute deviation mRNA mRNA vaccine mRNA-1273 neutralization Neutralization assay participant Participants reaction recipient recipients recruited respiratory response responses against Result SARS-CoV-2 Screen second dose severe acute respiratory syndrome Coronavirus Sex significantly significantly increased T-cell Response the vaccine titre vaccination Vaccine vaccinees were measured [DOI] 10.1016/j.cmi.2021.09.006 PMC 바로가기 [Article Type] Article